Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

New phase IIIb study of Tarceva in advanced NSCLC

Sep. 15, 2004

Novel HDAC inhibitors prepared and tested at Oxford GlycoSciences

Sep. 15, 2004

Bonefos accepted for priority review

Sep. 14, 2004

Assessment of survival of advanced NSCLC patients treated with gefitinib

Sep. 13, 2004

Insmed's rhIGFBP-3 enters phase I study

Sep. 13, 2004

Incyte patent covers novel antitumor agents targeting JNK signaling pathways

Sep. 13, 2004

GTI-2040 and capecitabine reported to be well tolerated in advanced kidney cancer

Sep. 13, 2004

Immune Response Corp. transfers cancer cell line vaccines rights to NovaRx

Sep. 13, 2004

Good safety profile found for EM-1421 in refractory head and neck cancer

Sep. 10, 2004

Callisto licenses annamycin from M.D. Anderson

Sep. 10, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...